Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
74 hedge funds and large institutions have $166M invested in Marinus Pharmaceuticals, Inc in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 11 reducing their positions, and 13 closing their positions.
392% more call options, than puts
Call options by funds: $5.33M | Put options by funds: $1.08M
200% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 11
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
7% more funds holding
Funds holding: 69 → 74 (+5)
10% less capital invested
Capital invested by funds: $184M → $166M (-$18.9M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$17.3M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$15.5M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$6.32M |
| 4 |
Millennium Management
New York
|
+$4.29M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$6.81M |
| 2 |
6CM
683 Capital Management
New York
|
-$4.35M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$3.14M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.23M |
| 5 |
AG
Artal Group
Luxembourg
|
-$1.04M |
MRNS Hedge Fund Activity: Q4 2022 in Review
74 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2022, worth a combined $166M — down 10% from $184M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new MRNS positions and 13 closed out — a net gain of 6 holders — while 33 added to existing stakes and 11 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $17.3M. The largest seller was VR Adviser, cutting an estimated $6.81M.
- 74 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2022, up from 69 in Q3 2022.
- Funds reported $166M of Marinus Pharmaceuticals, Inc stock for Q4 2022, down 10% quarter-over-quarter.
- 19 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2022 and 13 closed out, a net change of +6 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q4 2022 was Point72 Asset Management, an estimated $17.3M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q4 2022 was VR Adviser, an estimated $6.81M sold.
Based on aggregated 13F filings for Q4 2022.